Approval summary: Letrozole in the treatment of postmenopausal women with advanced breast cancer

Clinical Cancer Research

Volumn 8, Issue 3, 2002, Pages 665-669

  Cohen, Martin H ^a   Johnson, John R ^a   Li, Ning ^a   Chen, Gang ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; ESTRONE SULFATE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN; TAMOXIFEN CITRATE;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRALGIA; ARTICLE; BACKACHE; BONE PAIN; BREAST CANCER; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG MARKETING; DRUG MECHANISM; DRUG TOLERANCE; DYSPNEA; FATIGUE; FEMALE; HORMONE BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG APPROVAL; ENZYME INHIBITORS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0036304429     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Aromatase inhibitors in breast cancer
2. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer
3. Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients
4. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer
5. The importance of local synthesis of estrogen within the breast
6. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation
7. Detection of intraturnoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation
8. Estradiol formation from testosterone by continuously cultured human breast cancer cells
9. Estrogen depletion in advanced breast cancer: Why, how, and where we are going
10. Comparative bioavailability of letrozole underfed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration
11. Phase I study of the oral nonsteroldal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer
12. Letrozole (CGS 20267): A phase I study of a new potent oral aromatase inhibitor of breast cancer
13. Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients
14. Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study
15. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients
16. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma
17. Letrozole, a new oral aromatase inhibitor: Randomized trial comparing 2.5 mg daily, 0.5 mg daily, and aminoglutethimide in postmenopausal women with advanced breast cancer
18. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
19. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer